What are ADC's

Our services

ADC Review
is made possible by:

NCT01786096 (Clinical Trial / Denintuzumab mafodotin / SGN-CD19A / SGN-19A / hBU12-491)

Study Title
A Safety Study of SGN-CD19A for Leukemia and Lymphoma (NCT01786096)

Trial Description
This is a phase I, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A (also known as denintuzumab mafodotin/ SGN-CD19A/ hBU12-491) in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: Leukemia and Lymphoma
  • Interventions:
    • Drugs used in this trial
      • SGN-CD19A  (denintuzumab mafodotin; SGN-CD19A; hBU12-491)
  • Phase: I
  • Estimated Enrollment: 92
  • Start: February 2013
  • Estimated Completion: June 2016
  • Last verified: March 2016

Study Schematic 


Last Editorial review: July 29, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar